Safety and biodistribution of an equine infectious anemia virus-based gene therapy, RetinoStat(®), for age-related macular degeneration.
RetinoStat(®) is an equine infectious anemia virus-based lentiviral gene therapy vector that expresses the angiostatic proteins endostatin and angiostatin that is delivered via a subretinal injection for the treatment of the wet form of age-related macular degeneration. We initiated 6-month safety and biodistribution studies in two species; rhesus macaques and Dutch belted rabbits. After subretinal administration of RetinoStat the level of human endostatin and angiostatin proteins in the vitreous of treated rabbit eyes peaked at ∼1 month after dosing and remained elevated for the duration of the study. Regular ocular examinations revealed a mild to moderate transient ocular inflammation that resolved within 1 month of dosing in both species. There were no significant long-term changes in the electroretinograms or intraocular pressure measurements in either rabbits or macaques postdosing compared with the baseline reading in RetinoStat-treated eyes. Histological evaluation did not reveal any structural changes in the eye although there was an infiltration of mononuclear cells in the vitreous, retina, and choroid. No antibodies to any of the RetinoStat vector components or the transgenes could be detected in the serum from either species, and biodistribution analysis demonstrated that the RetinoStat vector was maintained within the ocular compartment. In summary, these studies found RetinoStat to be well tolerated, localized, and capable of persistent expression after subretinal delivery.
Oxford BioMedica (UK) Ltd, Oxford Science Park, Oxford, United Kingdom. k.binley@oxfordbiomedica.co.uk
Katie
K
Binley
Peter S
PS
Widdowson
Michelle
M
Kelleher
Jackie
J
de Belin
Julie
J
Loader
Georgina
G
Ferrige
Marie
M
Carlucci
Margaret
M
Esapa
Daniel
D
Chipchase
Diana
D
Angell-Manning
Scott
S
Ellis
Kyriacos
K
Mitrophanous
James
J
Miskin
Vlad
V
Bantseev
T Michael
TM
Nork
Paul
P
Miller
Stuart
S
Naylor
D043168:Angiostatins / Q000096:biosynthesis / Q000235:genetics; D000818:Animals; D043169:Endostatins / Q000096:biosynthesis / Q000235:genetics; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D006801:Humans; D004860:Infectious Anemia Virus, Equine; D007963:Leukocytes, Mononuclear / Q000378:metabolism / Q000473:pathology; D008253:Macaca mulatta; D008268:Macular Degeneration / Q000378:metabolism* / Q000473:pathology / Q000628:therapy*; D011817:Rabbits; D013997:Time Factors; D014822:Vitreous Body / Q000378:metabolism* / Q000473:pathology / Q000821:virology
D043169:Endostatins; D043168:Angiostatins